AR093468A1 - Derivados de piridina - Google Patents
Derivados de piridinaInfo
- Publication number
- AR093468A1 AR093468A1 ARP130104172A ARP130104172A AR093468A1 AR 093468 A1 AR093468 A1 AR 093468A1 AR P130104172 A ARP130104172 A AR P130104172A AR P130104172 A ARP130104172 A AR P130104172A AR 093468 A1 AR093468 A1 AR 093468A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- atom
- halogen atom
- alkyl group
- ring
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 18
- 125000005843 halogen group Chemical group 0.000 abstract 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 abstract 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 abstract 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- -1 atom halogen Chemical class 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 201000006334 interstitial nephritis Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 125000000686 lactone group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 150000003222 pyridines Chemical class 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
- Beans For Foods Or Fodder (AREA)
Abstract
Útil para tratar o prevenir enfermedades en las cuales está implicado el URAT1, incluyendo gota, hiperuricemia, hipertensión, enfermedades renales tales como nefritis intersticial y demás, diabetes, arteriosclerosis, Síndrome de Lesch-Nyhan y demás. Reivindicación 1: Un derivado de piridina representado por la fórmula (1) o una sal farmacéuticamente aceptable del mismo o un solvato del mismo; en la cual: A representa un enlace simple, un átomo de oxígeno, un átomo de azufre, NH o CH₂; R¹ representa un átomo de nitrógeno o CH; uno de X¹ a X⁵ representa un átomo de nitrógeno y los cuatro restantes representan CR²; R² representan independientemente, en cada caso, un átomo de hidrógeno, un grupo alquilo C₁₋₆, un grupo alquenilo C₂₋₆, un grupo alquinilo C₂₋₆, un átomo de halógeno, un grupo trifluorometilo, un grupo difluorometilo, un grupo ciano, un grupo alquilcarbonilo C₂₋₇, un grupo alquilsulfonilo C₁₋₆, un grupo nitro, un grupo amino, un grupo dialquilamino C₁₋₆ que opcionalmente pueden formar un anillo, un grupo formilo, un grupo hidroxilo, un grupo alcoxi C₁₋₆ (que puede estar opcionalmente sustituido con uno o más de un grupo hidroxilo, un grupo fenilo, un grupo ciclohexilo y un átomo de halógeno), un grupo alquiltio C₁₋₆, un grupo fenilo (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo C₁₋₆, un grupo alcoxi C₁₋₆ y un átomo de halógeno) o un grupo fenoxi (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo C₁₋₆, un grupo alcoxi C₁₋₆ y un átomo de halógeno), con la salvedad de que cuando dos CR²s están adyacentes, los dos R²s se pueden unir opcionalmente para formar un anillo; R³ representa un átomo de hidrógeno, un grupo alquilo C₁₋₆ (que puede estar opcionalmente sustituido con uno o más de un grupo hidroxilo, un grupo amino, un grupo dialquilamino C₁₋₆ que opcionalmente pueden formar un anillo, un anillo de imidazol, un anillo de pirazol, un anillo de pirrolidina, un anillo de piperidina, un anillo de morfolina y un anillo de piperazina (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo C₁₋₆ y un grupo alquilsulfonilo C₁₋₆)), un grupo alquenilo C₂₋₆, un grupo alquinilo C₂₋₆, un grupo alcoxi C₁₋₆ (que puede estar opcionalmente sustituido con uno o más de un grupo hidroxilo y un átomo de halógeno), un grupo alquilcarbonilo C₂₋₇, un grupo alquiltio C₁₋₆, un grupo alquilsulfinilo C₁₋₆, un átomo de halógeno, un grupo trifluorometilo, un grupo difluorometilo, un grupo ciano, un grupo fenilo (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo C₁₋₆, un grupo alcoxi C₁₋₆ y un átomo de halógeno), un grupo piridilo (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo C₁₋₆, un grupo alcoxi C₁₋₆ y un átomo de halógeno), un grupo fenoxi (que puede estar opcionalmente sustituido con uno o más de un grupo alquilo C₁₋₆, un grupo alcoxi C₁₋₆ y un átomo de halógeno), un grupo carboxilo o -CO₂R⁵; R⁴ representa un grupo carboxilo, un grupo tetrazolilo, -CONHSO₂R⁵, -CO₂R⁵ o cualquiera de los sustituyentes del grupo de fórmulas (2) con la salvedad de que cuando R³ es un grupo alquilo C₁₋₆ sustituido con un grupo hidroxilo y cuando R⁴ es un grupo carboxilo, luego R³ y R⁴ se pueden fusionar opcionalmente para formar un anillo de lactona; R⁵ en R³ y R⁴ representan independientemente, en cada caso, un grupo alquilo C₁₋₆; Z representa cualquiera de los sustituyentes del grupo de fórmulas (3), en la cual: R⁶ y R⁷ representan independientemente, en cada caso, un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆, un grupo trifluorometilo, un grupo trifluorometoxi o un grupo ciano, con la salvedad de que se excluye el caso en que R⁶ y R⁷ son simultáneamente átomos de hidrógeno; R⁸ representa un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ o un grupo trifluorometilo; R⁹ representa un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ o un grupo trifluorometilo; R¹⁰ representa un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ o un grupo trifluorometilo; R¹¹ y R¹² representan independientemente, en cada caso, un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ o un grupo trifluorometilo; R¹³ y R¹⁴ representan independientemente, en cada caso, un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ o un grupo trifluorometilo; R¹⁵ representa un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ o un grupo trifluorometilo; Y representa un átomo de hidrógeno o un grupo alquilo C₁₋₆; y W representa un átomo de azufre, un átomo de oxígeno o NR¹⁶ (donde R¹⁶ representa un átomo de hidrógeno, un grupo alquilo C₁₋₆ o un grupo bencilo).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012250661 | 2012-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093468A1 true AR093468A1 (es) | 2015-06-10 |
Family
ID=50731196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104172A AR093468A1 (es) | 2012-11-14 | 2013-11-13 | Derivados de piridina |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US9637469B2 (es) |
| EP (2) | EP2944633B1 (es) |
| JP (2) | JP5774238B2 (es) |
| KR (1) | KR20150082194A (es) |
| CN (2) | CN104797570B (es) |
| AR (1) | AR093468A1 (es) |
| AU (2) | AU2013345894B2 (es) |
| BR (1) | BR112015010977A2 (es) |
| CA (1) | CA2891408A1 (es) |
| CL (1) | CL2015001279A1 (es) |
| CY (1) | CY1120127T1 (es) |
| DK (1) | DK2944633T3 (es) |
| ES (1) | ES2662444T3 (es) |
| HR (1) | HRP20180451T1 (es) |
| HU (1) | HUE037736T2 (es) |
| IL (2) | IL238539A (es) |
| LT (1) | LT2944633T (es) |
| MA (1) | MA38078B1 (es) |
| ME (1) | ME03016B (es) |
| MX (1) | MX2015003672A (es) |
| NO (1) | NO2944633T3 (es) |
| NZ (1) | NZ708031A (es) |
| PE (1) | PE20150974A1 (es) |
| PH (1) | PH12015501037A1 (es) |
| PL (1) | PL2944633T3 (es) |
| PT (1) | PT2944633T (es) |
| RS (1) | RS57090B1 (es) |
| RU (1) | RU2640588C2 (es) |
| SA (1) | SA515360431B1 (es) |
| SG (2) | SG11201503770VA (es) |
| SI (1) | SI2944633T1 (es) |
| SM (1) | SMT201800322T1 (es) |
| TW (1) | TWI666205B (es) |
| UA (1) | UA117359C2 (es) |
| WO (1) | WO2014077285A1 (es) |
| ZA (1) | ZA201503322B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106458970B (zh) * | 2014-05-13 | 2019-09-13 | 帝人制药株式会社 | 吡啶衍生物的多晶形体及其制造方法 |
| CA2948797A1 (en) * | 2014-05-13 | 2015-11-19 | Teijin Pharma Limited | Pyrazine derivatives |
| AU2017233739A1 (en) | 2016-03-15 | 2018-09-20 | Bayer Cropscience Aktiengesellschaft | Substituted sulfonyl amides for controlling animal pests |
| CN107286156A (zh) * | 2016-04-05 | 2017-10-24 | 江苏新元素医药科技有限公司 | 新型urat1抑制剂及其在医药上的应用 |
| CN106008488B (zh) * | 2016-05-20 | 2018-10-30 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
| WO2017202291A1 (zh) * | 2016-05-23 | 2017-11-30 | 南京明德新药研发股份有限公司 | 噻吩化合物及其合成方法和其在医药上的应用 |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| UY37556A (es) | 2017-01-10 | 2018-07-31 | Bayer Ag | Derivados heterocíclicos como pesticidas |
| EP3568395A1 (de) | 2017-01-10 | 2019-11-20 | Bayer Aktiengesellschaft | Heterocyclen-derivate als schädlingsbekämpfungsmittel |
| CN108658879A (zh) * | 2017-03-29 | 2018-10-16 | 天津药物研究院有限公司 | 一种urat1抑制剂及其制备方法和用途 |
| CN109251184B (zh) * | 2017-07-13 | 2021-06-15 | 浙江海正药业股份有限公司 | 一种2-三氟甲基苯磺酰胺类衍生物的医药用途 |
| SMT202200134T1 (it) | 2018-03-08 | 2022-05-12 | Incyte Corp | Composti di amminopirazindiolo come inibitori di pi3k-y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| TWI820231B (zh) | 2018-10-11 | 2023-11-01 | 德商拜耳廠股份有限公司 | 用於製備經取代咪唑衍生物之方法 |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| BR112022008883A2 (pt) | 2019-11-07 | 2022-08-23 | Bayer Ag | Sulfonil amidas substituídas para controle de pragas animais |
| WO2022002818A1 (de) | 2020-07-02 | 2022-01-06 | Bayer Aktiengesellschaft | Heterocyclen-derivate als schädlingsbekämpfungsmittel |
| CN114315729B (zh) * | 2021-12-09 | 2024-01-26 | 大连理工大学 | 1-苄基-2，4-二芳基咪唑类化合物、合成方法及其在抗肿瘤上的应用 |
| WO2025026738A1 (en) | 2023-07-31 | 2025-02-06 | Bayer Aktiengesellschaft | 6-[5-(ethylsulfonyl)-1-methyl-1h-imidazol-4-yl]-7-methyl-3-(pentafluoroethyl)-7h-imidazo[4,5-c]pyridazine derivatives as pesticides |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1599032A (en) | 1977-03-04 | 1981-09-30 | May & Baker Ltd | Imidazole derivatives having herbicidal activity |
| JPS5671073A (en) | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | Imidazole derivative |
| PL149675B1 (pl) | 1986-03-10 | 1990-03-31 | Sposób wytwarzania nowych pochodnych kwasu 1-metyl0-1h-imidaz0l0karb0ksyl0weg0-5 | |
| US4770689A (en) | 1986-03-10 | 1988-09-13 | Janssen Pharmaceutica N.V. | Herbicidal imidazole-5-carboxylic acid derivatives |
| MY100938A (en) | 1986-06-06 | 1991-05-31 | Ciba Geigy Ag | Arylkylimidazole derivatives. |
| DD260928A5 (de) | 1986-06-06 | 1988-10-12 | Ciba-Geigy Ag,Ch | Verfahren zur herstellung neuer aralkylimidizolderivate |
| JPH08119936A (ja) | 1994-10-18 | 1996-05-14 | Fujisawa Pharmaceut Co Ltd | 複素環式誘導体 |
| IT1295405B1 (it) | 1997-09-30 | 1999-05-12 | Merck Sharp & Dohme Italia S P | Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di |
| EP1310485A4 (en) | 2000-07-28 | 2005-07-20 | Sumitomo Pharma | pyrrole |
| AU2002233698B2 (en) | 2001-02-22 | 2007-11-08 | Teijin Limited | Benzo(b)thiophene derivative and process for producing the same |
| AU2003902828A0 (en) * | 2003-06-05 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| JP5099794B2 (ja) * | 2007-11-27 | 2012-12-19 | アルデア バイオサイエンシーズ インク． | 新規化合物、組成物、及び使用方法 |
| US8450500B2 (en) * | 2008-06-04 | 2013-05-28 | Synta Pharmaceuticals Corp. | Pyrrole compounds that modulate HSP90 activity |
| EP2328879A4 (en) * | 2008-09-04 | 2012-05-09 | Ardea Biosciences Inc | CORRESPONDING COMPOUNDS, COMPOSITIONS, AND METHODS OF USE FOR MODULATING URIC ACID RATES |
| JP2010202575A (ja) | 2009-03-03 | 2010-09-16 | Takeda Chem Ind Ltd | 複素環化合物 |
| WO2011005969A2 (en) * | 2009-07-10 | 2011-01-13 | The General Hospital Corporation | Etomidate analogues that do not inhibit adrenocortical steroid synthesis |
| CN102035579B (zh) * | 2009-09-28 | 2014-09-03 | 夏普株式会社 | 信息反馈方法和用户设备 |
| AR081930A1 (es) * | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| JP5485811B2 (ja) * | 2010-06-23 | 2014-05-07 | 株式会社ジャパンディスプレイ | 双方向シフトレジスタ、及びこれを用いた画像表示装置 |
| PH12013500274A1 (en) * | 2010-08-11 | 2013-03-04 | Millennium Pharm Inc | Heteroaryls and uses thereof |
-
2013
- 2013-11-13 TW TW102141292A patent/TWI666205B/zh not_active IP Right Cessation
- 2013-11-13 UA UAA201505767A patent/UA117359C2/uk unknown
- 2013-11-13 AR ARP130104172A patent/AR093468A1/es unknown
- 2013-11-13 ES ES13854714T patent/ES2662444T3/es active Active
- 2013-11-13 PE PE2015000616A patent/PE20150974A1/es not_active Application Discontinuation
- 2013-11-13 PT PT138547146T patent/PT2944633T/pt unknown
- 2013-11-13 MA MA38078A patent/MA38078B1/fr unknown
- 2013-11-13 SI SI201330943T patent/SI2944633T1/en unknown
- 2013-11-13 NO NO13854714A patent/NO2944633T3/no unknown
- 2013-11-13 NZ NZ708031A patent/NZ708031A/en not_active IP Right Cessation
- 2013-11-13 RS RS20180390A patent/RS57090B1/sr unknown
- 2013-11-13 HR HRP20180451TT patent/HRP20180451T1/hr unknown
- 2013-11-13 ME MEP-2018-91A patent/ME03016B/me unknown
- 2013-11-13 RU RU2015122698A patent/RU2640588C2/ru active
- 2013-11-13 JP JP2014547007A patent/JP5774238B2/ja not_active Expired - Fee Related
- 2013-11-13 AU AU2013345894A patent/AU2013345894B2/en not_active Ceased
- 2013-11-13 LT LTEP13854714.6T patent/LT2944633T/lt unknown
- 2013-11-13 CA CA2891408A patent/CA2891408A1/en not_active Abandoned
- 2013-11-13 PL PL13854714T patent/PL2944633T3/pl unknown
- 2013-11-13 CN CN201380059519.0A patent/CN104797570B/zh not_active Expired - Fee Related
- 2013-11-13 CN CN201710933918.5A patent/CN107721931A/zh active Pending
- 2013-11-13 SG SG11201503770VA patent/SG11201503770VA/en unknown
- 2013-11-13 EP EP13854714.6A patent/EP2944633B1/en active Active
- 2013-11-13 EP EP18152142.8A patent/EP3339302A1/en not_active Withdrawn
- 2013-11-13 HU HUE13854714A patent/HUE037736T2/hu unknown
- 2013-11-13 SM SM20180322T patent/SMT201800322T1/it unknown
- 2013-11-13 WO PCT/JP2013/080706 patent/WO2014077285A1/ja not_active Ceased
- 2013-11-13 US US14/441,074 patent/US9637469B2/en not_active Expired - Fee Related
- 2013-11-13 MX MX2015003672A patent/MX2015003672A/es unknown
- 2013-11-13 BR BR112015010977A patent/BR112015010977A2/pt not_active Application Discontinuation
- 2013-11-13 SG SG10201705852PA patent/SG10201705852PA/en unknown
- 2013-11-13 KR KR1020157008457A patent/KR20150082194A/ko not_active Withdrawn
- 2013-11-13 DK DK13854714.6T patent/DK2944633T3/en active
-
2015
- 2015-01-16 JP JP2015007229A patent/JP6293068B2/ja not_active Expired - Fee Related
- 2015-04-30 IL IL238539A patent/IL238539A/en not_active IP Right Cessation
- 2015-05-08 PH PH12015501037A patent/PH12015501037A1/en unknown
- 2015-05-12 CL CL2015001279A patent/CL2015001279A1/es unknown
- 2015-05-13 ZA ZA2015/03322A patent/ZA201503322B/en unknown
- 2015-05-13 SA SA515360431A patent/SA515360431B1/ar unknown
- 2015-12-17 IL IL243193A patent/IL243193A0/en unknown
-
2017
- 2017-03-22 US US15/466,088 patent/US20170190694A1/en not_active Abandoned
- 2017-07-07 AU AU2017204665A patent/AU2017204665A1/en not_active Abandoned
-
2018
- 2018-04-10 CY CY20181100389T patent/CY1120127T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093468A1 (es) | Derivados de piridina | |
| AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
| AR093364A1 (es) | Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| AR112804A1 (es) | Compuestos de bisamida que activan el sarcómero y sus usos | |
| AR102094A1 (es) | Inhibidores de proteínas kras con una mutación g12c | |
| AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
| DK3357922T3 (da) | 2-((5-(1-(3-(methylsulfonyl)propyl)piperidin-4-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8h)-on-derivater og relaterede forbindelser som cdk4-inhibitorer til behandling af tumorer | |
| AR090488A1 (es) | Derivados de n-ciclobutilbenzamida, un proceso para su obtencion, intermediarios para su sintesis, composiciones pesticidas y farmaceuticas que los comprenden y metodos para controlar daños debidos a una plaga y/u hongos | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR088748A1 (es) | Macrociclos como inhibidores del factor xia | |
| AR101208A1 (es) | Espirocicloheptanos como inhibidores de rock | |
| AR103969A1 (es) | Inmunomoduladores | |
| AR094346A1 (es) | Derivados de azaindol como inhibidores de las proteína quinasas | |
| AR093036A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| AR112099A1 (es) | Imidazopirimidinas diazabicíclicas sustituidas y su uso | |
| AR067327A1 (es) | Derivados de piperidina / piperazina | |
| AR096654A1 (es) | Derivados de benzimidazol como inhibidores selectivos de proteína quinasa | |
| AR091208A1 (es) | Derivados de piperidina | |
| AR087354A1 (es) | Inhibidores selectivos de la proteina quinasa | |
| AR097755A1 (es) | Derivados sustituidos de fenilalanina como moduladores del factor xia | |
| AR093035A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| AR096423A1 (es) | Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona | |
| AR089853A1 (es) | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |